Mar 28 |
Acelyrin GAAP EPS of -$5.43
|
Mar 28 |
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
|
Mar 27 |
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
|
Mar 20 |
Acelyrin gains after positive phase 1/2 data for thyroid eye disease drug
|
Mar 20 |
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
|
Mar 13 |
Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis
|
Mar 11 |
Acelyrin jumps 10% on izokibep psoriatic arthritis results
|
Mar 11 |
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
|
Mar 11 |
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
|
Mar 11 |
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
|